Global Reach Health News

March 26, 2021

Abecma Approved to Treat Multiple Myeloma

March 26, 2021 – The U.S. FDA has approved Abecma (idecabtagene vicleucel), manufactured by Bristol Myers Squibb and bluebird bio, Inc., to treat relapsed or refractory multiple